

## Detection of *bla*<sub>PER-1</sub> & *bla*<sub>Oxa10</sub> among imipenem resistant isolates of *Pseudomonas aeruginosa* isolated from burn patients hospitalized in Shiraz Burn Hospital

Amir Emami<sup>1,2</sup>, Abdollah Bazargani<sup>2</sup>, Ali Akbar Mohammadi<sup>3\*</sup>,  
Mitra Zardosht<sup>3</sup>, Seyed Morteza Seyed Jafari<sup>3</sup>

<sup>1</sup>Shiraz Burn Research Center, Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran. <sup>2</sup>Department of Bacteriology and Virology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran. <sup>3</sup>Shiraz Burn Research Center, Division of plastic and reconstructive Surgery, Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: March 2013, Accepted: January 2014

### ABSTRACT

**Background and Objectives:** *Pseudomonas aeruginosa* is one of the most important Gram negative opportunistic bacteria which causes infection among burn patients. Resistance to the antibiotics in this group of bacteria is increased due to the activity of extended spectrum  $\beta$ -lactamase (ESBLs) genes. In the current study, we investigated the prevalence of two genes (*bla*<sub>PER-1</sub> & *bla*<sub>Oxa10</sub>) related  $\beta$ -lactamase genes among imipenem resistance clinical isolates of *P. aeruginosa* in hospitalized patients.

**Materials and Methods:** From May 2010 to March 2011, 270 *P. aeruginosa* isolated from hospitalized burned patients' wounds in Shiraz Burn Hospital, were tested for Imipenem resistance by disk diffusion method. Presence of ESBLs exo-enzyme, *bla*<sub>PER-1</sub> and *bla*<sub>Oxa10</sub> genes were also evaluated in the resistant isolate.

**Results:** 210 (77.7%) of 270 *P. aeruginosa* isolates were resistant to imipenem. *bla*<sub>PER-1</sub> and *bla*<sub>Oxa10</sub> were detected among 168 (80.0%) of imipenem resistant isolates. Furthermore, 160 (76.2%) of them had *bla*<sub>Oxa10</sub> gene and 84 (40.0%) of them had *bla*<sub>PER-1</sub> while 63 (30.0%) resistant isolates contained both genes simultaneously.

**Conclusion:** This study showed a high prevalence of *bla*<sub>PER-1</sub> and *bla*<sub>Oxa10</sub> genes in hospitalized burn patients in south west of Iran. Therefore, it's highly recommended to perform such tests routinely to evaluate the resistance pattern in order to better antibiotic selection in the burned patients.

**Keywords:** *bla*<sub>Oxa10</sub>, *bla*<sub>PER-1</sub>, Burn, ESBLs, Resistance, *Pseudomonas aeruginosa*

### INTRODUCTION

*Pseudomonas aeruginosa* is a Gram negative

opportunistic human pathogen, which causes various acute and chronic nosocomial infections such as pneumonia, urinary tract and wound infections in immunocompromised hosts, particularly in burn hospitalized patients (1).

These infections are responsible for significant human mortality, morbidity, prolonged hospital stays and increased health care costs (2,3). This organism possesses different factors that promote adherence to host cells and mucosal tissues, damage host tissue, elicit inflammation and disrupt defense

\*Corresponding author: Ali Akbar Mohammadi  
Address: Shiraz Burn Research Center, Division of plastic and reconstructive Surgery, Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.  
Tel: +98- 917-113-3639  
Fax: +98-71-38208880  
E-mail: mohamadiaa@sums.ac.ir

**Table 1.** Primer seq. target genes, product size and PCR protocol

Bacteria Gene Primer	Seq. (5/-3/ direction)	cycle profile (35X)	Product size
<i>P. aeruginosa</i>			
<i>bla</i> <sub>OXA-10</sub> <sup>F</sup>	TAT CGC GTG TCT TTC GAG TA	610C/1min- 720/2min- 950/1min	760 bp
<i>bla</i> <sub>OXA-10</sub> <sup>R</sup>	TTA GCC ACC AAT GAT GCC C		
<i>bla</i> <sub>PER-1</sub> <sup>F</sup>	ATG AAT GTC ATT ATA AAA GCT	520C/1min- 720/2min- 950/1min	927 bp
<i>bla</i> <sub>PER-1</sub> <sup>R</sup>	TA ATT TGG GCT TAG G		

mechanisms. This conditions aggravate in burn patients due to impairment of the skin barrier in burn patients and frequent scrubbing, debridement and manipulation of the burn site (1). Resistance of *P. aeruginosa* to a wide spectrum of antibiotics has become a major clinical concern worldwide (1, 2). The extended spectrum  $\beta$ -lactamases (ESBLs), may lead *P. aeruginosa* to be resistant to  $\beta$ -lactam antibiotics, including penicillins, cephalosporins and monobactams (4,5).

OXA and PER can be mentioned as the two of important  $\beta$ -lactamase enzymes, in *P. aeruginosa*, (3, 4). *bla*<sub>PER-1</sub> was the first group of this gene reported from France in 1991 in a single *P. aeruginosa* isolate from a Turkish patient (3). *P. aeruginosa* strains containing *bla*<sub>PER-1</sub> are highly resistant to  $\beta$ -lactamase, and have strong hydrolytic activity against cephalosporins but can not hydrolyze carbapenems and cephamycins (5). Another group of such enzymes which has high incidence in Enterobacteriaceae especially in *P. aeruginosa* is OXA. Owing to hydrolytic activity OXA-10 (a class D  $\beta$ -lactamase) is responsible for a high resistance to amino-group antibiotics, carboxy-penicillins, ureido-penicillins and cephalosporins in *P. aeruginosa* isolates (6).

Due to importance of the carbapenems in resistance infections management, and increasing of the imipenem resistance ESBL *P. aeruginosa* strains, finding the true frequency of such enzymes is mandatory. The purpose of the present study was to investigate the prevalence of these two  $\beta$ -lactamase genes (*bla*<sub>PER-1</sub> and *bla*<sub>Oxa-10</sub>) in imipenem resistant clinical isolates of *P. aeruginosa* in hospitalized patients in a main burn center of southwest of Iran.

## MATERIALS AND METHODS

**Bacterial Isolation.** The study included 270 *P. aeruginosa* isolates that were recovered consecutively from clinical sites of separate patients' wounds

hospitalized in Shiraz Burn Hospital (the main burn center in southwest of Iran) from May 2010 to March 2011. Collected strains were assessed with routine microbiology methods like Gram stain, pigment production on Muller-Hinton agar media, Oxidase test and non-fermentative result in TSI media. Then, PCR based assay was performed by specific primers for 16s rDNA (7) to confirm presence of *P. aeruginosa*. Confirmed strains were stored at -200C in Trypticase Soy Broth containing 10% glycerol.

**Antimicrobial susceptibility testing.** Isolated strains were tested for their resistance to imipenem using the disc diffusion method (DD), according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (8). Resistance to imipenem, were also evaluated for ESBL production using the combination disc diffusion method (CDD), recommended by the CLSI guidelines (9). In this step, antibiotic disks (aztreonam (/30 $\mu$ g), ceftazidime (/30 $\mu$ g) cephotaxime (/30 $\mu$ g)) were placed around a clavulanic acid (15 $\mu$ g) disk on 10 cm Mueller-Hinton agar plates inoculated with 0.5 McFarland suspensions of the isolates, with 30 mm distance between each disk. After the incubation time (18 hours/37°C) inhibition zone diameters were measured to the minimum distance. Difference of 5mm  $\geq$  in the zone between each disk with clavulanic acid disk compare to another side of the disk showed that the strain is ESBL positive. For ESBL negative control, *P. aeruginosa* (ATCC 27853) was used.

**Detection of *bla*<sub>OXA-10</sub> and *bla*<sub>PER-1</sub> PCR.** Imipenem-Resistant *P. aeruginosa* strains were refreshed in Muller-Hinton broth for about 4 hours and their DNA were extracted with Accuprep® Genomic DNA Extraction Kit (Bioneer-USA) according to the manufacture protocol. To evaluate the presence of *bla*<sub>OXA-10</sub> *bla*<sub>PER-1</sub> genes in these strains, the PCR was performed with the specific primers for these regions according to the Table-1.

## RESULTS


In this cross-sectional of 270 isolates of *P. aeruginosa*, 210 (77.7%) were resistant to the imipenem. According to the results of CDD screen, 168(80.0%) isolates were ESBL producing strains. 160 (76.2%) of them contain *bla*<sub>OXA-10</sub> and 84 (40%) of resistant isolates contain *bla*<sub>PER-1</sub> related genes, and 63(30.0%) of them contain both genes. 148(92.5%) of 160 *bla*<sub>OXA-10</sub> containing isolates, and all of *bla*<sub>PER-1</sub> containing isolates produced ESBL (Figs. 1- 2).

## DISCUSSION

Burn injury is a major public health problem in many countries, and requires immediate specialized care in order to minimize mortality and morbidity (10,11). It is estimated that 75% of all deaths following burn injury are related to infection (12). The infection in such patients is difficult to control due to the presence of dead burn eschar, and moist environment, that act as a good growth medium for microbes. Prolonged hospital stay and invasive diagnostic and therapeutic procedures (13, 14).

*P. aeruginosa*, known as major colonizer of the burn wound, is able to accumulate different resistance and virulence factors, thrives on moist burn wound surface and survives well in the hospital environment, once it is established (14). Burn hospitals often harbor multidrug-resistant *P. aeruginosa* that can serve as the source of infection (2). Previous studies in Iran confirmed resistance to many antibiotics used routinely for treatment of burn wounds infected by *P. aeruginosa*. Hadadi *et al.* showed that *P. aeruginosa* isolates were resistance to ceftizoxime (99%), ceftazidime (59.6%), ticarcilin (50%), ceftriaxone (44.3%), and cefoperazone (37.5%) (15). According to a study conducted in Shiraz Burn hospital in 2006 by Japoni A *et al.* almost all *P. aeruginosa* isolated from burn patients were resistant to all tested anti-Pseudomonal antibiotics except carbapenems (meropenem and imipenem) (16).

Carbapenems are useful in treatment of some cases of multi-drug resistant strains of *P. aeruginosa* (16). The resistance of *P. aeruginosa* was 48% against imipenem in a study conducted by Singh *et al.* in Korea in 2001 (17). In another study in Iran in 2009 Shahcheraghi *et al.* reported 75% resistance for imipenem in *P. aeruginosa* isolated from nosocomial



**Fig. 1.** PCR amplification of *bla*<sub>PER-1</sub> and *bla*<sub>OXA-10</sub> genes. 1, 3, 7, 15: No. of positive samples for *per-1* (927bp) - 11, 25, 42, 57: No. of positive samples for *bla*<sub>OXA-10</sub> (760 bp)

La: DNA ladder, NC: negative control, C+: Positive control.

sources (12). In the current study 210 (77.7%) of 270 isolated *P. aeruginosa*, were resistant to imipenem.

It seems that most of this multidrug resistance reflects the accumulation of multiple mutations and acquirement of many resistance genes (2). Different studies evaluated the *P. aeruginosa* resistant strains in different world centers specially in ICU & Burn wards so far (5,16,18), which showed different pattern for the resistance of this bacteria to the different antibiotics and the frequency of the important  $\beta$ -lactamases (such as *bla*<sub>PER-1</sub> and *bla*<sub>OXA-10</sub>) among resistant isolates. According to the results of CDD screening in our study, 168 (80.0%) isolates from 210 Imipenem resistant isolates were ESBL producing strains. Mirsalehian *et al.* highlighted that 39.41% of the *P. aeruginosa* strains isolated from hospitalized burn patients in Tehran were ESBL producers (16).

For many years, PER  $\beta$ -lactamases were thought to be significant only in Turkey (*PER-1*) and Argentina (*PER-2*) (5, 18, 19). Since 1995, PER-1 producing organisms have been disseminating in Italy (20, 21), France (21), Spain (22), Romania (23), Korea (24), Japan (26), and China (27). Bacteria with the OXA (a class D  $\beta$ -lactamase) have evolved to destroy  $\beta$ -lactam

## Result




Fig. 2. Number of Imipenem resistant isolates, ESBL producing isolates in Imipenem Resistance's, number of *bla<sub>PER-1</sub>* and *bla<sub>OXA-10</sub>* related genes.

antibiotics, and presented high levels of resistance to a broad spectrum of  $\beta$ -lactam antibiotics (28, 29).

Mirsalehian *et al.* in 2010 stated that 74.62% and 49.25% of the isolated *P. aeruginosa* strains from hospitalized burn patients in Tehran contain *bla<sub>PER-1</sub>* and *bla<sub>OXA-10</sub>* gene, respectively (17). In addition, Vahaboglu *et al.* detected PER-1-type  $\beta$ -lactamases in 11% (40/367) of *P. aeruginosa* strains (30). While in our study, 160 (76.2%) of the resistant isolates contain *bla<sub>OXA-10</sub>* and 84 (40%) of resistant isolates contain *bla<sub>PER-1</sub>* related genes, and 63 (30.0%) of them contains both related genes simultaneously. 148 (92.5%) of 160 *bla<sub>OXA-10</sub>* containing isolates, and all of *bla<sub>PER-1</sub>* containing isolates were ESBL producing.

The results of our study showed a high prevalence of the imipenem resistant strains in burn patients, which is an alarming sign and should be taken into the consideration, because increasing of the antimicrobial resistant bacteria isolated from burn patients is an important issue (13).

The accumulation of multiple mutations and acquirement of resistance genes is believed as one of the most important reasons for the multidrug resistance (2). Hence, it is very important to set up a strict and logical infection control program to detect the source of infection, bacteriological profile, antibiogram of burn wound isolates and find the responsible genes for the antimicrobial resistant in order to decrease the incidence of nosocomial infections in hospitalized burn patients and help the clinicians to better drug selection for this kind of patients.

## ACKNOWLEDGMENT

This study was financially supported by the Shiraz Burn research center, Shiraz University of Medical Sciences, Shiraz, Iran. We appreciate close collaboration of the Bacteriology & Virology department of Shiraz medical school for providing a comfortable environment for the laboratory performing steps.

## REFERENCES

- Empel J, Filczak K, Mrówka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of *Pseudomonas aeruginosa* infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. *J Clin Microbiol* 2007;45:2829-2834.
- Patzer JA, Dzierzanowska D. Increase of imipenem resistance among *Pseudomonas aeruginosa* isolates from a Polish paediatric hospital (1993-2002). *Int J Antimicrob Agents* 2007;29:153-158.
- Aktaş Z, Poirel L, Salcioğlu M, Özcan PE, Midilli K, Bal C, et al. PER-1- and OXA-10-like beta-lactamases in ceftazidime-resistant *Pseudomonas aeruginosa* isolates from intensive care unit patients in Istanbul, Turkey. *Clin Microbiol Infect* 2005;11:193-198.
- Bahar G, Erač B, Mert A, Gülay Z. PER-1 production in a urinary isolate of *Providencia rettgeri*. *J Chemother* 2004;16:343-6.
- Danel F, Hall LM, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10- lactamase, isolated from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1999;43:1362-6.
- Bert F, Branger C, Lambert-Zechovsky N. Identification of PSE and OXA  $\beta$ -lactamase genes in *Pseudomonas*

- aeruginosa* using PCR-restriction fragment length polymorphism. *J Antimicrob Chemother* 2002;50:11-18.
7. Spilker T, Coenye T, Vandamme P, LiPuma JJ. PCR-based assay for differentiation of *Pseudomonas aeruginosa* from other *Pseudomonas* species recovered from cystic fibrosis patients. *J Clin Microbiol* 2004;42:2074-9.
  8. Performance standards for antimicrobial susceptibility testing; Twentieth-second information supplement in Wayne, PA, USA: CLSI 2007. 180.
  9. Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J. Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by enterobacteriaceae. *J Clin Microbiol* 2011;49:1048-1057.
  10. Mohammadi AA, Seyed Jafari SM, Kiasat M, Pakyari MR, Ahrari I. Efficacy of debridement and wound cleansing with 2% hydrogen peroxide on graft take in the chronic-colonized burn wounds; a randomized controlled clinical trial. *Burns* 2013;39:1131-6.
  11. Mohammadi AA, Seyed Jafari SM, Kiasat M, Tavakkolian AR, Imani MT, Ayaz M, et al. Effect of fresh human amniotic membrane dressing on graft take in patients with chronic burn wounds compared with conventional methods. *Burns* 2013;39:349-53.
  12. Shahcheraghi F, Nikbin VS, Feizabadi MM., Prevalence of ESBLs genes among multidrug-resistant isolates of *Pseudomonas aeruginosa* isolated from patients in Tehran. *Microb Drug Resist* 2009;15:37-39.
  13. Bayram Y, Parlak M, Aypak C, Bayram I. Three-year review of bacteriological profile and antibiogram of burn wound isolates in Van, Turkey. *Int J Med Sci* 2013;10: 19-23.
  14. Jácome PR, Alves LR, Cabral AB, Lopes AC, Maciel MA. Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in *Pseudomonas aeruginosa* clinical isolates from Recife, State of Pernambuco, Brazil. *Rev Soc Bras Med Trop* 2012;45: 707-12.
  15. Hadadi A, Rasoulinejad M, Maleki Z, Yonesian M, Shirani A, Kourorian Z. Antimicrobial resistance pattern of Gram-negative bacilli of nosocomial origin at 2 university hospitals in Iran. *Diagn Microbiol Infect Dis* 2008;60:301-305.
  16. Japoni A, Alborzi A, Kalani M, Nasiri J, Hayati M, Farshad S. Susceptibility patterns and cross-resistance of antibiotics against *Pseudomonas aeruginosa* isolated from burn patients in the South of Iran. *Burns* 2006;32:343-7.
  17. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing *Pseudomonas aeruginosa* strains isolated from burn patients. *Burns* 2010;36:70-74.
  18. Bauernfeind A, Stemplinger I, Jungwirth R, Mangold P, Amann S, Akalin E, et al. Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase. *Antimicrob Agents Chemother* 1996;40:616-620.
  19. Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H. PER-1 is still widespread in Turkish hospitals among *Pseudomonas aeruginosa* and *Acinetobacter* spp. *FEMS Microbiol Lett* 2005;249(2):241-5.
  20. Docquier JD, Luzzaro F, Amicosante G, Toniolo A, Rossolini GM. Multidrug-resistant *Pseudomonas aeruginosa* producing PER-1 extended-spectrum serine-beta-lactamase and VIM-2 metallo-beta-lactamase. *Emerg Infect Dis* 2001;7:910-1.
  21. Endimiani A, Luzzaro F, Pini B, Amicosante G, Rossolini GM, Toniolo AQ. *Pseudomonas aeruginosa* bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. *BMC Infect Dis* 2006 16;6:52.
  22. De Champs C, Chanal C, Sirot D, Baraduc R, Romaszko JP, Bonnet R, et al. Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. *J Antimicrob Chemother* 2004;54:634-639.
  23. Miró E, Mirelis B, Navarro F, Rivera A, Mesa RJ, Roig MC, et al. Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. *J Antimicrob Chemother* 2005;56:1152-5.
  24. Naas T, Nordmann P, Heidt A. Intercountry transfer of PER-1 extended-spectrum beta-lactamase-producing *Acinetobacter baumannii* from Romania. *Int J Antimicrob Agents* 2007;29:226-228.
  25. Jeong SH, Bae IK, Kwon SB, Lee K, Yong D, Woo GJ, et al. Investigation of a nosocomial outbreak of *Acinetobacter baumannii* producing PER-1 extended-spectrum beta-lactamase in an intensive care unit. *J Hosp Infect* 2005;59:242-8.
  26. Yamano Y, Nishikawa T, Fujimura T, Yutsudou T, Tsuji M, Miwa H. Occurrence of PER-1 producing clinical isolates of *Pseudomonas aeruginosa* in Japan and their susceptibility to doripenem. *J Antibiot* 2006;59:791-6.
  27. Hou TW, Yin XL, Jiang CY, Wang ZH, Chen QK, Chen X, et al. Microbiology and clinical analysis of six cases of hospital-acquired pneumonia caused by *Acinetobacter baumannii*. *Zhonghua Jie He He Hu Xi Za Zhi* 2007;30:35-9.
  28. Bush K, Mobashery S. How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. *Adv Exp Med Biol* 1999;456:71-98.
  29. Maveyraud L, Golemi D, Kotra LP, Tranier S, Vakulenko S, Mobashery S., et al. Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from *Pseudomonas aeruginosa*. *Structure* 2000;8:1289-1298.
  30. Vahaboglu H, Ozturk R, Aygün G, Coskuncan F, Yaman A, Kaygusuz A, et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial *Acinetobacter* and *Pseudomonas aeruginosa* isolates in Turkey: a nationwide multicenter study. *Antimicrob Agents Chemother* 1997;41:2265-9.